licensingGSK adds liver candidate from Wave RNA partnershipGSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, triggering a $12 million (€11 million) milestone payment to the U.S.-based b … more ➔
clinical dataHighlight Therapeutics’ skin cancer injections show promise in Phase 2bSpain’s Highlight Therapeutics reported that its lead candidate, BO-112, met its Phase 2b endpoint in localized basal cell carcinoma, with 61% of evaluable patients achieving a response. more ➔
clinical dataBoehringer, Zealand obesity drug face tolerability questions after Phase 3 successBoehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with overweight or obesity and type 2 diabetes, but gastrointestinal side effects … more ➔
licensingSanofi pays $1B upfront to expand Regeneron alliance beyond DupixentSanofi will pay Regeneron Pharmaceuticals $1 billion upfront (€0.9 billion) to expand the alliance that led to the blockbuster Dupixent with four antibody candidates designed to work longer between … more ➔
clinical dataAtrogi’s muscle drug shows early power signal ahead of Phase 2Swedish biotech Atrogi says its oral drug ATR-258 increased lower-extremity muscle power by about 13% after eight weeks in a study of 13 people with overweight or obesity. Participants also lost an average … more ➔
multiple sclerosisImmunic CEO: “We want to understand MS patients better than anyone”Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy … more ➔
licensingAstraZeneca boards the PD-1/VEGF ship with $2B Summit investmentAstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates. more ➔
clinical datauniQure falls as Huntington’s gene therapy shows mixed resultsuniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The … more ➔
fundraisingAnaCardio raises €62.5M to test heart failure drugSwedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient pop … more ➔
startupsAptadir secures €40M for gene-reactivating RNA drugsAptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene silenced in Fragile X syndrome. more ➔
